nodes	percent_of_prediction	percent_of_DWPC	metapath
Fludarabine—POLA1—seminal vesicle—testicular cancer	0.0158	0.101	CbGeAlD
Fludarabine—SLC28A3—female gonad—testicular cancer	0.0132	0.0842	CbGeAlD
Fludarabine—RRM1—seminal vesicle—testicular cancer	0.0125	0.08	CbGeAlD
Fludarabine—DCK—embryo—testicular cancer	0.0104	0.0661	CbGeAlD
Fludarabine—DCK—seminal vesicle—testicular cancer	0.00972	0.0621	CbGeAlD
Fludarabine—POLA1—female gonad—testicular cancer	0.00926	0.0592	CbGeAlD
Fludarabine—RRM1—gonad—testicular cancer	0.00904	0.0578	CbGeAlD
Fludarabine—POLA1—testis—testicular cancer	0.00821	0.0525	CbGeAlD
Fludarabine—SLC29A1—gonad—testicular cancer	0.00735	0.047	CbGeAlD
Fludarabine—RRM1—female gonad—testicular cancer	0.00735	0.047	CbGeAlD
Fludarabine—DCK—gonad—testicular cancer	0.00703	0.0449	CbGeAlD
Fludarabine—RRM1—testis—testicular cancer	0.00652	0.0416	CbGeAlD
Fludarabine—SLC29A1—female gonad—testicular cancer	0.00598	0.0382	CbGeAlD
Fludarabine—POLA1—lymph node—testicular cancer	0.00595	0.038	CbGeAlD
Fludarabine—DCK—female gonad—testicular cancer	0.00571	0.0365	CbGeAlD
Fludarabine—SLC29A1—testis—testicular cancer	0.0053	0.0339	CbGeAlD
Fludarabine—DCK—Doxorubicin—Epirubicin—testicular cancer	0.00523	0.519	CbGdCrCtD
Fludarabine—DCK—testis—testicular cancer	0.00506	0.0323	CbGeAlD
Fludarabine—DCK—Epirubicin—Doxorubicin—testicular cancer	0.00484	0.481	CbGdCrCtD
Fludarabine—RRM1—lymph node—testicular cancer	0.00473	0.0302	CbGeAlD
Fludarabine—SLC29A1—lymph node—testicular cancer	0.00384	0.0245	CbGeAlD
Fludarabine—DCK—lymph node—testicular cancer	0.00367	0.0234	CbGeAlD
Fludarabine—Pruritus—Bleomycin—testicular cancer	0.000639	0.000767	CcSEcCtD
Fludarabine—Feeling abnormal—Ifosfamide—testicular cancer	0.000636	0.000763	CcSEcCtD
Fludarabine—Nausea—Vinblastine—testicular cancer	0.000635	0.000762	CcSEcCtD
Fludarabine—Anorexia—Cisplatin—testicular cancer	0.000634	0.000761	CcSEcCtD
Fludarabine—Discomfort—Etoposide—testicular cancer	0.000628	0.000754	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Epirubicin—testicular cancer	0.000626	0.000751	CcSEcCtD
Fludarabine—Hypersensitivity—Dactinomycin—testicular cancer	0.000621	0.000745	CcSEcCtD
Fludarabine—Confusional state—Etoposide—testicular cancer	0.000615	0.000738	CcSEcCtD
Fludarabine—Body temperature increased—Ifosfamide—testicular cancer	0.00061	0.000732	CcSEcCtD
Fludarabine—Pancytopenia—Methotrexate—testicular cancer	0.00061	0.000732	CcSEcCtD
Fludarabine—Anaphylactic shock—Etoposide—testicular cancer	0.00061	0.000732	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000606	0.000728	CcSEcCtD
Fludarabine—Infection—Etoposide—testicular cancer	0.000606	0.000727	CcSEcCtD
Fludarabine—Asthenia—Dactinomycin—testicular cancer	0.000605	0.000725	CcSEcCtD
Fludarabine—Dysphagia—Epirubicin—testicular cancer	0.000601	0.000721	CcSEcCtD
Fludarabine—Dysuria—Methotrexate—testicular cancer	0.000601	0.000721	CcSEcCtD
Fludarabine—Neutropenia—Methotrexate—testicular cancer	0.000601	0.000721	CcSEcCtD
Fludarabine—Dehydration—Doxorubicin—testicular cancer	0.000598	0.000718	CcSEcCtD
Fludarabine—Paraesthesia—Cisplatin—testicular cancer	0.000598	0.000717	CcSEcCtD
Fludarabine—Thrombocytopenia—Etoposide—testicular cancer	0.000597	0.000716	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Methotrexate—testicular cancer	0.000597	0.000716	CcSEcCtD
Fludarabine—Liver function test abnormal—Doxorubicin—testicular cancer	0.000594	0.000713	CcSEcCtD
Fludarabine—Dyspnoea—Cisplatin—testicular cancer	0.000593	0.000712	CcSEcCtD
Fludarabine—Hyperhidrosis—Etoposide—testicular cancer	0.00059	0.000707	CcSEcCtD
Fludarabine—Angina pectoris—Epirubicin—testicular cancer	0.000586	0.000703	CcSEcCtD
Fludarabine—Anorexia—Etoposide—testicular cancer	0.000581	0.000697	CcSEcCtD
Fludarabine—Toxic epidermal necrolysis—Doxorubicin—testicular cancer	0.000579	0.000695	CcSEcCtD
Fludarabine—Decreased appetite—Cisplatin—testicular cancer	0.000579	0.000694	CcSEcCtD
Fludarabine—Bronchitis—Epirubicin—testicular cancer	0.000578	0.000694	CcSEcCtD
Fludarabine—Diarrhoea—Dactinomycin—testicular cancer	0.000576	0.000692	CcSEcCtD
Fludarabine—Pneumonia—Methotrexate—testicular cancer	0.000576	0.000691	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Cisplatin—testicular cancer	0.000575	0.00069	CcSEcCtD
Fludarabine—Vomiting—Bleomycin—testicular cancer	0.000574	0.000689	CcSEcCtD
Fludarabine—Pancytopenia—Epirubicin—testicular cancer	0.000571	0.000685	CcSEcCtD
Fludarabine—Rash—Bleomycin—testicular cancer	0.00057	0.000684	CcSEcCtD
Fludarabine—Pain—Cisplatin—testicular cancer	0.000569	0.000683	CcSEcCtD
Fludarabine—Dermatitis—Bleomycin—testicular cancer	0.000569	0.000683	CcSEcCtD
Fludarabine—Hypersensitivity—Ifosfamide—testicular cancer	0.000569	0.000683	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Methotrexate—testicular cancer	0.000568	0.000681	CcSEcCtD
Fludarabine—Renal failure—Methotrexate—testicular cancer	0.000563	0.000676	CcSEcCtD
Fludarabine—Dysuria—Epirubicin—testicular cancer	0.000562	0.000674	CcSEcCtD
Fludarabine—Neutropenia—Epirubicin—testicular cancer	0.000562	0.000674	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Epirubicin—testicular cancer	0.000559	0.00067	CcSEcCtD
Fludarabine—Stomatitis—Methotrexate—testicular cancer	0.000558	0.00067	CcSEcCtD
Fludarabine—Dysphagia—Doxorubicin—testicular cancer	0.000556	0.000667	CcSEcCtD
Fludarabine—Asthenia—Ifosfamide—testicular cancer	0.000554	0.000665	CcSEcCtD
Fludarabine—Feeling abnormal—Cisplatin—testicular cancer	0.000549	0.000658	CcSEcCtD
Fludarabine—Paraesthesia—Etoposide—testicular cancer	0.000548	0.000657	CcSEcCtD
Fludarabine—Pruritus—Ifosfamide—testicular cancer	0.000546	0.000655	CcSEcCtD
Fludarabine—Haematuria—Methotrexate—testicular cancer	0.000546	0.000655	CcSEcCtD
Fludarabine—Dyspnoea—Etoposide—testicular cancer	0.000544	0.000652	CcSEcCtD
Fludarabine—Hyperglycaemia—Epirubicin—testicular cancer	0.000542	0.000651	CcSEcCtD
Fludarabine—Angina pectoris—Doxorubicin—testicular cancer	0.000542	0.00065	CcSEcCtD
Fludarabine—Epistaxis—Methotrexate—testicular cancer	0.00054	0.000648	CcSEcCtD
Fludarabine—Pneumonia—Epirubicin—testicular cancer	0.000539	0.000647	CcSEcCtD
Fludarabine—Nausea—Bleomycin—testicular cancer	0.000537	0.000644	CcSEcCtD
Fludarabine—Vomiting—Dactinomycin—testicular cancer	0.000536	0.000643	CcSEcCtD
Fludarabine—Bronchitis—Doxorubicin—testicular cancer	0.000535	0.000642	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Epirubicin—testicular cancer	0.000531	0.000638	CcSEcCtD
Fludarabine—Rash—Dactinomycin—testicular cancer	0.000531	0.000637	CcSEcCtD
Fludarabine—Decreased appetite—Etoposide—testicular cancer	0.00053	0.000636	CcSEcCtD
Fludarabine—Diarrhoea—Ifosfamide—testicular cancer	0.000528	0.000634	CcSEcCtD
Fludarabine—Pancytopenia—Doxorubicin—testicular cancer	0.000528	0.000634	CcSEcCtD
Fludarabine—Renal failure—Epirubicin—testicular cancer	0.000527	0.000632	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Etoposide—testicular cancer	0.000526	0.000632	CcSEcCtD
Fludarabine—Body temperature increased—Cisplatin—testicular cancer	0.000526	0.000631	CcSEcCtD
Fludarabine—Fatigue—Etoposide—testicular cancer	0.000526	0.000631	CcSEcCtD
Fludarabine—Neuropathy peripheral—Epirubicin—testicular cancer	0.000525	0.00063	CcSEcCtD
Fludarabine—Stomatitis—Epirubicin—testicular cancer	0.000522	0.000627	CcSEcCtD
Fludarabine—Constipation—Etoposide—testicular cancer	0.000521	0.000626	CcSEcCtD
Fludarabine—Pain—Etoposide—testicular cancer	0.000521	0.000626	CcSEcCtD
Fludarabine—Urinary tract infection—Epirubicin—testicular cancer	0.000521	0.000625	CcSEcCtD
Fludarabine—Neutropenia—Doxorubicin—testicular cancer	0.00052	0.000624	CcSEcCtD
Fludarabine—Dysuria—Doxorubicin—testicular cancer	0.00052	0.000624	CcSEcCtD
Fludarabine—Upper respiratory tract infection—Doxorubicin—testicular cancer	0.000517	0.00062	CcSEcCtD
Fludarabine—Haemoglobin—Methotrexate—testicular cancer	0.000517	0.00062	CcSEcCtD
Fludarabine—Haemorrhage—Methotrexate—testicular cancer	0.000514	0.000617	CcSEcCtD
Fludarabine—Haematuria—Epirubicin—testicular cancer	0.000511	0.000613	CcSEcCtD
Fludarabine—Pharyngitis—Methotrexate—testicular cancer	0.00051	0.000612	CcSEcCtD
Fludarabine—Epistaxis—Epirubicin—testicular cancer	0.000506	0.000607	CcSEcCtD
Fludarabine—Sinusitis—Epirubicin—testicular cancer	0.000503	0.000603	CcSEcCtD
Fludarabine—Feeling abnormal—Etoposide—testicular cancer	0.000503	0.000603	CcSEcCtD
Fludarabine—Hyperglycaemia—Doxorubicin—testicular cancer	0.000502	0.000602	CcSEcCtD
Fludarabine—Nausea—Dactinomycin—testicular cancer	0.0005	0.000601	CcSEcCtD
Fludarabine—Pneumonia—Doxorubicin—testicular cancer	0.000499	0.000599	CcSEcCtD
Fludarabine—Visual impairment—Methotrexate—testicular cancer	0.000495	0.000595	CcSEcCtD
Fludarabine—Stevens-Johnson syndrome—Doxorubicin—testicular cancer	0.000492	0.00059	CcSEcCtD
Fludarabine—Vomiting—Ifosfamide—testicular cancer	0.000491	0.000589	CcSEcCtD
Fludarabine—Hypersensitivity—Cisplatin—testicular cancer	0.00049	0.000588	CcSEcCtD
Fludarabine—Renal failure—Doxorubicin—testicular cancer	0.000487	0.000585	CcSEcCtD
Fludarabine—Rash—Ifosfamide—testicular cancer	0.000487	0.000584	CcSEcCtD
Fludarabine—Dermatitis—Ifosfamide—testicular cancer	0.000486	0.000584	CcSEcCtD
Fludarabine—Erythema multiforme—Methotrexate—testicular cancer	0.000486	0.000583	CcSEcCtD
Fludarabine—Neuropathy peripheral—Doxorubicin—testicular cancer	0.000486	0.000583	CcSEcCtD
Fludarabine—Haemoglobin—Epirubicin—testicular cancer	0.000484	0.00058	CcSEcCtD
Fludarabine—Stomatitis—Doxorubicin—testicular cancer	0.000483	0.00058	CcSEcCtD
Fludarabine—Body temperature increased—Etoposide—testicular cancer	0.000482	0.000578	CcSEcCtD
Fludarabine—Urinary tract infection—Doxorubicin—testicular cancer	0.000482	0.000578	CcSEcCtD
Fludarabine—Haemorrhage—Epirubicin—testicular cancer	0.000481	0.000577	CcSEcCtD
Fludarabine—Hypoaesthesia—Epirubicin—testicular cancer	0.000479	0.000574	CcSEcCtD
Fludarabine—Asthenia—Cisplatin—testicular cancer	0.000478	0.000573	CcSEcCtD
Fludarabine—Pharyngitis—Epirubicin—testicular cancer	0.000478	0.000573	CcSEcCtD
Fludarabine—Haematuria—Doxorubicin—testicular cancer	0.000473	0.000567	CcSEcCtD
Fludarabine—Epistaxis—Doxorubicin—testicular cancer	0.000468	0.000561	CcSEcCtD
Fludarabine—Sinusitis—Doxorubicin—testicular cancer	0.000465	0.000558	CcSEcCtD
Fludarabine—Visual impairment—Epirubicin—testicular cancer	0.000464	0.000556	CcSEcCtD
Fludarabine—Chills—Methotrexate—testicular cancer	0.000461	0.000554	CcSEcCtD
Fludarabine—Nausea—Ifosfamide—testicular cancer	0.000459	0.00055	CcSEcCtD
Fludarabine—Diarrhoea—Cisplatin—testicular cancer	0.000455	0.000546	CcSEcCtD
Fludarabine—Erythema multiforme—Epirubicin—testicular cancer	0.000455	0.000546	CcSEcCtD
Fludarabine—Alopecia—Methotrexate—testicular cancer	0.000454	0.000545	CcSEcCtD
Fludarabine—Hypersensitivity—Etoposide—testicular cancer	0.000449	0.000539	CcSEcCtD
Fludarabine—Malnutrition—Methotrexate—testicular cancer	0.000448	0.000537	CcSEcCtD
Fludarabine—Haemoglobin—Doxorubicin—testicular cancer	0.000447	0.000537	CcSEcCtD
Fludarabine—Haemorrhage—Doxorubicin—testicular cancer	0.000445	0.000534	CcSEcCtD
Fludarabine—Hypoaesthesia—Doxorubicin—testicular cancer	0.000443	0.000532	CcSEcCtD
Fludarabine—Pharyngitis—Doxorubicin—testicular cancer	0.000442	0.00053	CcSEcCtD
Fludarabine—Asthenia—Etoposide—testicular cancer	0.000438	0.000525	CcSEcCtD
Fludarabine—Chills—Epirubicin—testicular cancer	0.000432	0.000518	CcSEcCtD
Fludarabine—Pruritus—Etoposide—testicular cancer	0.000431	0.000518	CcSEcCtD
Fludarabine—Arrhythmia—Epirubicin—testicular cancer	0.00043	0.000516	CcSEcCtD
Fludarabine—Visual impairment—Doxorubicin—testicular cancer	0.000429	0.000515	CcSEcCtD
Fludarabine—Alopecia—Epirubicin—testicular cancer	0.000425	0.00051	CcSEcCtD
Fludarabine—Vomiting—Cisplatin—testicular cancer	0.000423	0.000508	CcSEcCtD
Fludarabine—Erythema multiforme—Doxorubicin—testicular cancer	0.000421	0.000505	CcSEcCtD
Fludarabine—Rash—Cisplatin—testicular cancer	0.00042	0.000504	CcSEcCtD
Fludarabine—Dermatitis—Cisplatin—testicular cancer	0.000419	0.000503	CcSEcCtD
Fludarabine—Malnutrition—Epirubicin—testicular cancer	0.000419	0.000503	CcSEcCtD
Fludarabine—Diarrhoea—Etoposide—testicular cancer	0.000417	0.000501	CcSEcCtD
Fludarabine—Ill-defined disorder—Methotrexate—testicular cancer	0.000415	0.000498	CcSEcCtD
Fludarabine—Anaemia—Methotrexate—testicular cancer	0.000414	0.000496	CcSEcCtD
Fludarabine—Malaise—Methotrexate—testicular cancer	0.000404	0.000484	CcSEcCtD
Fludarabine—Leukopenia—Methotrexate—testicular cancer	0.000401	0.000481	CcSEcCtD
Fludarabine—Chills—Doxorubicin—testicular cancer	0.000399	0.000479	CcSEcCtD
Fludarabine—Arrhythmia—Doxorubicin—testicular cancer	0.000398	0.000477	CcSEcCtD
Fludarabine—Nausea—Cisplatin—testicular cancer	0.000395	0.000474	CcSEcCtD
Fludarabine—Alopecia—Doxorubicin—testicular cancer	0.000393	0.000472	CcSEcCtD
Fludarabine—Cough—Methotrexate—testicular cancer	0.000391	0.000469	CcSEcCtD
Fludarabine—Ill-defined disorder—Epirubicin—testicular cancer	0.000389	0.000466	CcSEcCtD
Fludarabine—Convulsion—Methotrexate—testicular cancer	0.000388	0.000465	CcSEcCtD
Fludarabine—Vomiting—Etoposide—testicular cancer	0.000388	0.000465	CcSEcCtD
Fludarabine—Malnutrition—Doxorubicin—testicular cancer	0.000388	0.000465	CcSEcCtD
Fludarabine—Anaemia—Epirubicin—testicular cancer	0.000387	0.000465	CcSEcCtD
Fludarabine—Agitation—Epirubicin—testicular cancer	0.000385	0.000462	CcSEcCtD
Fludarabine—Rash—Etoposide—testicular cancer	0.000384	0.000461	CcSEcCtD
Fludarabine—Dermatitis—Etoposide—testicular cancer	0.000384	0.000461	CcSEcCtD
Fludarabine—Headache—Etoposide—testicular cancer	0.000382	0.000458	CcSEcCtD
Fludarabine—Myalgia—Methotrexate—testicular cancer	0.000381	0.000457	CcSEcCtD
Fludarabine—Arthralgia—Methotrexate—testicular cancer	0.000381	0.000457	CcSEcCtD
Fludarabine—Malaise—Epirubicin—testicular cancer	0.000378	0.000453	CcSEcCtD
Fludarabine—Discomfort—Methotrexate—testicular cancer	0.000376	0.000452	CcSEcCtD
Fludarabine—Leukopenia—Epirubicin—testicular cancer	0.000375	0.00045	CcSEcCtD
Fludarabine—Confusional state—Methotrexate—testicular cancer	0.000368	0.000442	CcSEcCtD
Fludarabine—Cough—Epirubicin—testicular cancer	0.000365	0.000439	CcSEcCtD
Fludarabine—Anaphylactic shock—Methotrexate—testicular cancer	0.000365	0.000438	CcSEcCtD
Fludarabine—Convulsion—Epirubicin—testicular cancer	0.000363	0.000435	CcSEcCtD
Fludarabine—Infection—Methotrexate—testicular cancer	0.000363	0.000435	CcSEcCtD
Fludarabine—Nausea—Etoposide—testicular cancer	0.000362	0.000435	CcSEcCtD
Fludarabine—Ill-defined disorder—Doxorubicin—testicular cancer	0.00036	0.000431	CcSEcCtD
Fludarabine—Nervous system disorder—Methotrexate—testicular cancer	0.000358	0.00043	CcSEcCtD
Fludarabine—Anaemia—Doxorubicin—testicular cancer	0.000358	0.00043	CcSEcCtD
Fludarabine—Thrombocytopenia—Methotrexate—testicular cancer	0.000358	0.000429	CcSEcCtD
Fludarabine—Arthralgia—Epirubicin—testicular cancer	0.000357	0.000428	CcSEcCtD
Fludarabine—Myalgia—Epirubicin—testicular cancer	0.000357	0.000428	CcSEcCtD
Fludarabine—Agitation—Doxorubicin—testicular cancer	0.000356	0.000427	CcSEcCtD
Fludarabine—Hyperhidrosis—Methotrexate—testicular cancer	0.000353	0.000424	CcSEcCtD
Fludarabine—Discomfort—Epirubicin—testicular cancer	0.000352	0.000423	CcSEcCtD
Fludarabine—Malaise—Doxorubicin—testicular cancer	0.000349	0.000419	CcSEcCtD
Fludarabine—Anorexia—Methotrexate—testicular cancer	0.000348	0.000418	CcSEcCtD
Fludarabine—Leukopenia—Doxorubicin—testicular cancer	0.000347	0.000416	CcSEcCtD
Fludarabine—Confusional state—Epirubicin—testicular cancer	0.000345	0.000414	CcSEcCtD
Fludarabine—Oedema—Epirubicin—testicular cancer	0.000342	0.00041	CcSEcCtD
Fludarabine—Anaphylactic shock—Epirubicin—testicular cancer	0.000342	0.00041	CcSEcCtD
Fludarabine—Infection—Epirubicin—testicular cancer	0.00034	0.000407	CcSEcCtD
Fludarabine—Cough—Doxorubicin—testicular cancer	0.000338	0.000406	CcSEcCtD
Fludarabine—Convulsion—Doxorubicin—testicular cancer	0.000336	0.000403	CcSEcCtD
Fludarabine—Nervous system disorder—Epirubicin—testicular cancer	0.000335	0.000402	CcSEcCtD
Fludarabine—Thrombocytopenia—Epirubicin—testicular cancer	0.000335	0.000402	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000333	0.000399	CcSEcCtD
Fludarabine—Hyperhidrosis—Epirubicin—testicular cancer	0.00033	0.000397	CcSEcCtD
Fludarabine—Arthralgia—Doxorubicin—testicular cancer	0.00033	0.000396	CcSEcCtD
Fludarabine—Myalgia—Doxorubicin—testicular cancer	0.00033	0.000396	CcSEcCtD
Fludarabine—Paraesthesia—Methotrexate—testicular cancer	0.000328	0.000394	CcSEcCtD
Fludarabine—Discomfort—Doxorubicin—testicular cancer	0.000326	0.000391	CcSEcCtD
Fludarabine—Anorexia—Epirubicin—testicular cancer	0.000326	0.000391	CcSEcCtD
Fludarabine—Dyspnoea—Methotrexate—testicular cancer	0.000326	0.000391	CcSEcCtD
Fludarabine—Dyspepsia—Methotrexate—testicular cancer	0.000322	0.000386	CcSEcCtD
Fludarabine—Confusional state—Doxorubicin—testicular cancer	0.000319	0.000383	CcSEcCtD
Fludarabine—Decreased appetite—Methotrexate—testicular cancer	0.000318	0.000381	CcSEcCtD
Fludarabine—Anaphylactic shock—Doxorubicin—testicular cancer	0.000316	0.00038	CcSEcCtD
Fludarabine—Oedema—Doxorubicin—testicular cancer	0.000316	0.00038	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000315	0.000378	CcSEcCtD
Fludarabine—Fatigue—Methotrexate—testicular cancer	0.000315	0.000378	CcSEcCtD
Fludarabine—Infection—Doxorubicin—testicular cancer	0.000314	0.000377	CcSEcCtD
Fludarabine—Pain—Methotrexate—testicular cancer	0.000312	0.000375	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000311	0.000374	CcSEcCtD
Fludarabine—Nervous system disorder—Doxorubicin—testicular cancer	0.00031	0.000372	CcSEcCtD
Fludarabine—Thrombocytopenia—Doxorubicin—testicular cancer	0.00031	0.000372	CcSEcCtD
Fludarabine—Paraesthesia—Epirubicin—testicular cancer	0.000307	0.000368	CcSEcCtD
Fludarabine—Hyperhidrosis—Doxorubicin—testicular cancer	0.000306	0.000367	CcSEcCtD
Fludarabine—Dyspnoea—Epirubicin—testicular cancer	0.000305	0.000366	CcSEcCtD
Fludarabine—Anorexia—Doxorubicin—testicular cancer	0.000301	0.000362	CcSEcCtD
Fludarabine—Feeling abnormal—Methotrexate—testicular cancer	0.000301	0.000361	CcSEcCtD
Fludarabine—Dyspepsia—Epirubicin—testicular cancer	0.000301	0.000361	CcSEcCtD
Fludarabine—Decreased appetite—Epirubicin—testicular cancer	0.000297	0.000357	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000295	0.000354	CcSEcCtD
Fludarabine—Fatigue—Epirubicin—testicular cancer	0.000295	0.000354	CcSEcCtD
Fludarabine—Constipation—Epirubicin—testicular cancer	0.000292	0.000351	CcSEcCtD
Fludarabine—Pain—Epirubicin—testicular cancer	0.000292	0.000351	CcSEcCtD
Fludarabine—Body temperature increased—Methotrexate—testicular cancer	0.000289	0.000346	CcSEcCtD
Fludarabine—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000288	0.000346	CcSEcCtD
Fludarabine—Paraesthesia—Doxorubicin—testicular cancer	0.000284	0.000341	CcSEcCtD
Fludarabine—Dyspnoea—Doxorubicin—testicular cancer	0.000282	0.000338	CcSEcCtD
Fludarabine—Feeling abnormal—Epirubicin—testicular cancer	0.000282	0.000338	CcSEcCtD
Fludarabine—Dyspepsia—Doxorubicin—testicular cancer	0.000278	0.000334	CcSEcCtD
Fludarabine—Decreased appetite—Doxorubicin—testicular cancer	0.000275	0.00033	CcSEcCtD
Fludarabine—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000273	0.000328	CcSEcCtD
Fludarabine—Fatigue—Doxorubicin—testicular cancer	0.000273	0.000327	CcSEcCtD
Fludarabine—Pain—Doxorubicin—testicular cancer	0.00027	0.000325	CcSEcCtD
Fludarabine—Constipation—Doxorubicin—testicular cancer	0.00027	0.000325	CcSEcCtD
Fludarabine—Body temperature increased—Epirubicin—testicular cancer	0.00027	0.000324	CcSEcCtD
Fludarabine—Hypersensitivity—Methotrexate—testicular cancer	0.000269	0.000323	CcSEcCtD
Fludarabine—Asthenia—Methotrexate—testicular cancer	0.000262	0.000314	CcSEcCtD
Fludarabine—Feeling abnormal—Doxorubicin—testicular cancer	0.000261	0.000313	CcSEcCtD
Fludarabine—Pruritus—Methotrexate—testicular cancer	0.000258	0.00031	CcSEcCtD
Fludarabine—Hypersensitivity—Epirubicin—testicular cancer	0.000252	0.000302	CcSEcCtD
Fludarabine—Body temperature increased—Doxorubicin—testicular cancer	0.00025	0.0003	CcSEcCtD
Fludarabine—Diarrhoea—Methotrexate—testicular cancer	0.00025	0.0003	CcSEcCtD
Fludarabine—Asthenia—Epirubicin—testicular cancer	0.000245	0.000294	CcSEcCtD
Fludarabine—Pruritus—Epirubicin—testicular cancer	0.000242	0.00029	CcSEcCtD
Fludarabine—Diarrhoea—Epirubicin—testicular cancer	0.000234	0.000281	CcSEcCtD
Fludarabine—Hypersensitivity—Doxorubicin—testicular cancer	0.000233	0.00028	CcSEcCtD
Fludarabine—Vomiting—Methotrexate—testicular cancer	0.000232	0.000279	CcSEcCtD
Fludarabine—Rash—Methotrexate—testicular cancer	0.00023	0.000276	CcSEcCtD
Fludarabine—Dermatitis—Methotrexate—testicular cancer	0.00023	0.000276	CcSEcCtD
Fludarabine—Headache—Methotrexate—testicular cancer	0.000229	0.000275	CcSEcCtD
Fludarabine—Asthenia—Doxorubicin—testicular cancer	0.000227	0.000272	CcSEcCtD
Fludarabine—Pruritus—Doxorubicin—testicular cancer	0.000224	0.000269	CcSEcCtD
Fludarabine—Vomiting—Epirubicin—testicular cancer	0.000217	0.000261	CcSEcCtD
Fludarabine—Nausea—Methotrexate—testicular cancer	0.000217	0.00026	CcSEcCtD
Fludarabine—Diarrhoea—Doxorubicin—testicular cancer	0.000216	0.00026	CcSEcCtD
Fludarabine—Rash—Epirubicin—testicular cancer	0.000216	0.000259	CcSEcCtD
Fludarabine—Dermatitis—Epirubicin—testicular cancer	0.000215	0.000258	CcSEcCtD
Fludarabine—Headache—Epirubicin—testicular cancer	0.000214	0.000257	CcSEcCtD
Fludarabine—Nausea—Epirubicin—testicular cancer	0.000203	0.000244	CcSEcCtD
Fludarabine—Vomiting—Doxorubicin—testicular cancer	0.000201	0.000241	CcSEcCtD
Fludarabine—Rash—Doxorubicin—testicular cancer	0.000199	0.000239	CcSEcCtD
Fludarabine—Dermatitis—Doxorubicin—testicular cancer	0.000199	0.000239	CcSEcCtD
Fludarabine—Headache—Doxorubicin—testicular cancer	0.000198	0.000238	CcSEcCtD
Fludarabine—Nausea—Doxorubicin—testicular cancer	0.000188	0.000225	CcSEcCtD
